{"owner": "ArrayExpress Uploader", "pop_total": 0, "id": 6948, "factors": [{"GSM866205": {"TREATMENT": "interleukin 3"}}, {"GSM866205": {"TREATMENT": "interleukin 3"}}, {"GSM866205": {"TREATMENT": "interleukin 3"}}, {"GSM866205": {"TREATMENT": "interleukin 3"}}, {"GSM866205": {"TREATMENT": "interleukin 3"}}, {"GSM866205": {"TREATMENT": "interleukin 3"}}, {"GSM8662": {"TREATMENT": "interleukin 3 and interleukin 33"}}, {"GSM8662": {"TREATMENT": "interleukin 3 and interleukin 33"}}, {"GSM8662": {"TREATMENT": "interleukin 3 and interleukin 33"}}, {"GSM8662": {"TREATMENT": "interleukin 3 and interleukin 33"}}, {"GSM8662": {"TREATMENT": "interleukin 3 and interleukin 33"}}, {"GSM8662": {"TREATMENT": "interleukin 3 and interleukin 33"}}], "ownerprofile_id": "arrayexpress_sid", "platform": 6, "summary_wrapped": "Interleukin-33 (IL-33) is elevated in afflicted tissues of patients with mast cell-dependent chronic allergic diseases. Based on its...", "pubmed_id": 23248261, "geo_gse_id": "E-GEOD-39382", "owner_profile": "/profile/8773/arrayexpressuploader", "factor_count": 1, "sample_count": 12, "tags": ["bone", "bone marrow", "cell", "disease", "interleukin", "mast cell"], "lastmodified": "Dec.12, 2014", "is_default": false, "geo_gds_id": "", "slug": "il-33-induces-a-hypo-responsive-human-mast-cell-ph", "geo_id_plat": "E-GEOD-39382_A-AFFY-45", "name": "IL-33 induces a hypo-responsive human mast cell phenotype", "created": "Nov.12, 2014", "summary": "Interleukin-33 (IL-33) is elevated in afflicted tissues of patients with mast cell-dependent chronic allergic diseases. Based on its acute effects on mouse mast cells (MCs), IL-33 is thought to play a role in the pathogenesis of allergic disease through MC activation. However, the manifestations of chronic IL-33 exposure on human MC function, which best reflect the conditions associated with chronic allergic disease, are unknown. We now find that long-term exposure of human and mouse MCs to IL-33 results in a substantial reduction of MC activation in response to antigen. This reduction required >72 h exposure to IL-33 for onset and 1-2 wk for reversion following IL-33 removal. This hypo-responsive phenotype was determined to be a consequence of MyD88-dependent attenuation of signaling processes necessary for MC activation including antigen-mediated calcium mobilization and cytoskeletal reorganization; potentially as a consequence of down-regulation of the expression of PLCg1 and Hck. These findings suggest that IL-33 may play a protective, rather than a causative role in MC activation under chronic conditions and, furthermore, reveal regulated plasticity in the MC activation phenotype. The ability to down-regulate MC activation in this manner may provide alternative approaches for treatment of MC-driven disease. Mouse bone marrow-derived mast cells treated with IL3 or IL3+IL33. 6 replicates each.", "source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-39382", "species": "mouse", "sample_source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-39382/samples/"}